Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen M Ansell

Showing results (11-20 of 555) with videos related to

Pageof 56
Sort By:
The Lancet. Oncology|March 8, 2014
Follicular lymphoma: watch and wait is watch and worryStephen M Ansell
Current Opinion in Hematology|June 8, 2015
Targeting immune checkpoints in lymphomaStephen M Ansell
Blood|October 12, 2013
Two targets for the price of oneStephen M Ansell
Oncology (Williston Park, N.Y.)|January 11, 2012
Innate immune B cells gone badStephen M Ansell
Cancer Immunology Research|May 3, 2019
The Highs and Lows of Immune-Checkpoint Blockade in LymphomaStephen M Ansell
American Journal of Hematology|November 16, 2012
Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and managementStephen M Ansell
American Journal of Hematology|September 6, 2024
Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and managementStephen M Ansell
American Journal of Hematology|October 10, 2022
Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and managementStephen M Ansell
Mayo Clinic Proceedings|August 8, 2015
Non-Hodgkin Lymphoma: Diagnosis and TreatmentStephen M Ansell
American Journal of Hematology|October 28, 2015
Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyondStephen M Ansell
Pageof 56

Showing results (11-20 of 555) with videos related to

Sort By:
Pageof 56
The Lancet. Oncology|March 8, 2014
Follicular lymphoma: watch and wait is watch and worryStephen M Ansell
Current Opinion in Hematology|June 8, 2015
Targeting immune checkpoints in lymphomaStephen M Ansell
Blood|October 12, 2013
Two targets for the price of oneStephen M Ansell
Oncology (Williston Park, N.Y.)|January 11, 2012
Innate immune B cells gone badStephen M Ansell
Cancer Immunology Research|May 3, 2019
The Highs and Lows of Immune-Checkpoint Blockade in LymphomaStephen M Ansell
American Journal of Hematology|November 16, 2012
Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and managementStephen M Ansell
American Journal of Hematology|September 6, 2024
Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and managementStephen M Ansell
American Journal of Hematology|October 10, 2022
Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and managementStephen M Ansell
Mayo Clinic Proceedings|August 8, 2015
Non-Hodgkin Lymphoma: Diagnosis and TreatmentStephen M Ansell
American Journal of Hematology|October 28, 2015
Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyondStephen M Ansell
Pageof 56